News

SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO
Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...
Devdiscourse13h
Merck's Bold $3.9 Billion Bid on SpringWorks: A Game-Changer in Rare Cancer Therapies
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
Fierce Pharma2d
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
GEN - Genetic Engineering and Biotechnology News17h
Merck KGaA to Acquire SpringWorks for $3.9B, Expanding Rare Cancer Footprint
Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.
Stamford-based drug developer for rare cancers and tumors sold for $3.9 billion to German company
After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.
The Global Legal Post3h
Sullivan & Cromwell, Goodwin Procter guide Merck’s $3.9bn US biotech buy
Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks ...
Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
Devdiscourse3d
Global Health Updates: From Mergers to Measles and Medicine
The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...